|MDACC Study No:||2010-0187 (clinicaltrials.gov NCT No: NCT01191749)|
|Title:||PHASE II PILOT STUDY OF ALEMTUZUMAB IN PATIENTS WITH LOW OR INT - 1 RISK MEYLODYSPLASTIC SYNDROME (MDS), APLASTIC ANEMIA (AA), OR T - CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA (T - LGL)|
|Principal Investigator:||Tapan Kadia|
|Study Description:||The goal of this clinical research study is to determine the effectiveness of |
alemtuzumab in patients with aplastic anemia, MDS, or T-Cell large granular
lymphocytic leukemia. The safety of alemtuzumab will also be studied.